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Background: Pompe disease (Glycogen storage disease type II, GSD II, acid alpha-glucosidase deficiency, acid
maltase deficiency, OMIM # 232300) is an autosomal-recessive lysosomal storage disorder due to a deficiency of
acid alpha-glucosidase (GAA, acid maltase, EC 3.2.1.20, Swiss-Prot P10253). Clinical manifestations are dominated by
progressive weakness of skeletal muscle throughout the clinical spectrum. In addition, the classic infantile form is
characterised by hypertrophic cardiomyopathy.
Methods: In a cross-sectional single-centre study we clinically assessed 3 patients with classic infantile Pompe
disease and 39 patients with non-classic presentations, measured their acid alpha-glucosidase activities and
analysed their GAA genes.
Results: Classic infantile patients had nearly absent residual enzyme activities and a typical clinical course with
hypertrophic cardiomyopathy until the beginning of therapy. The disease manifestations in non-classic patients
were heterogeneous. There was a broad variability in the decline of locomotive and respiratory function. The age of
onset ranged from birth to late adulthood and correlated with enzyme activities. Molecular analysis revealed as
many as 33 different mutations, 14 of which are novel. All classic infantile patients had two severe mutations.
The most common mutation in the non-classic group was c.-32-13T>G. It was associated with a milder course in
this subgroup.
Conclusions: Disease manifestation strongly correlates with the nature of the GAA mutations, while the variable
progression in non-classic Pompe disease is likely to be explained by yet unknown modifying factors. This study
provides the first comprehensive dataset on the clinical course and the mutational spectrum of Pompe disease
in Germany.
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Pompe disease (Glycogen storage disease type II, GSD
II, acid alpha-glucosidase deficiency, acid maltase defi-
ciency, OMIM # 232300) is an autosomal-recessive lyso-
somal storage disorder caused by a deficiency of acid
alpha-glucosidase (GAA, acid maltase, EC 3.2.1.20, Swiss-
Prot P10253) [1]. Accumulation of glycogen in various
tissues leads to a broad and continuous spectrum of clin-
ical phenotypes that can be categorised according to clin-
ical features into classic infantile and non-classic forms.
Patients with non-classic disease can further be divided
over those with a childhood, juvenile or adult course [1].
All patients show progressive skeletal muscle weakness
which results in a decline of locomotive and respiratory
functions. In addition, the classic infantile form is char-
acterised by hypertrophic cardiomyopathy [1]. Classic
infantile patients show first symptoms within the first
months of life with heart failure and a profound muscle
weakness. Without therapy, most of classic infantile
patients die within the first year of life [2,3].
Among patients with non-classic forms complaints
may begin at any time between early childhood and late
adulthood [4,5]. With disease progression patients de-
velop progressive myopathy that may result in immobil-
isation and respiratory insufficiency [4].
The frequency of Pompe disease varies among differ-
ent ethnic groups and is estimated as 1/138,000 for clas-
sic infantile and 1/57,000 for non-classic patients in the
Netherlands [1].
The GAA gene (OMIM # 606800) is located on
chromosome 17q25.2-q25.3 [6]. With a length of ~20 kb
it contains 20 exons and encodes for a cDNA of
3.6 kb, the start codon beginning at position 33 of exon 2
[7]. The resulting product is a protein of 952 amino
acids [8].
Until now, 361 variants have been described in the
GAA gene, 78 of which are polymorphisms while 248
are considered as disease-causing mutations [9]. Muta-
tions are randomly spread over the whole gene and
typically private. However, some mutations appear with
considerable frequency in distinct ethnic groups. For
instance, in cohorts of non-classic Caucasian patients
c.-32-13 T>G is the most common mutation with a
frequency of 34-47% [10–14]. This mutation leads to
impaired splicing of exon 2 with about 10% of normally
spliced products [15].
The clinical course of Pompe disease primarily
depends on the residual acid alpha-glucosidase activity
as determined by the genotype [10,16,17]. However, this
correlation is afflicted with a broad variability in enzyme
activities as well as in clinical signs, particularly in
patients with the non-classic forms [18].
Here we describe disease presentation, enzymatic and
molecular findings in a German cohort consisting of 3patients with classic infantile Pompe disease and 39
patients with non-classic disease presentation.
Materials and methods
Patients and clinical data
Forty-two patients with a clinical and enzymatic diagno-
sis of Pompe disease were included in this study.
Patients are usually categorised with respect to age of
onset, extent of organ involvement and disease progres-
sion [1]. We distinguished patients with a classic infant-
ile course that are severely affected by hypertrophic
cardiomyopathy, onset in the first month of life and
rapid progression from those with a non-classic course
with predominant muscle involvement but without
hypertrophic cardiomyopathy. Non-classic disease
includes the childhood, juvenile and adult forms, which
are not unambiguously distinguished in the literature.
We therefore defined the childhood forms by having
motor delay and progression of muscle weakness before
achievement of motor milestones. The juvenile forms
were defined by progression of muscle weakness after
achievement of motor milestones but before the end of
growth. Adult forms were defined by having a progres-
sion of muscle weakness not until the end of growth. It
is of note that non-classic patients may have an earlier
onset followed by temporary regression of symptoms be-
fore muscle weakness becomes progressive.
In non-classic patients all data were collected in the
observation period before starting enzyme replacement
therapy, when they only received supportive care. Since we
initiated enzyme replacement therapy with alglucosidase
alpha in all classic infantile patients shortly after referring
to our centre, data on their natural course are limited and
amended by a description of the course under ERT.
Clinical data were retrospectively collected from health
records. Assessment included physical examination,
manual muscle testing using the Medical Research
Council (MRC) grading scale for different muscle
groups, the Walton & Gardner-Medwin scale, and the
per cent predicted forced vital capacity (FVC) in sitting
and supine position. A total MRC-score was defined as
the mean of MRC-grades of neck flexion, shoulder ab-
duction, elbow flexion, hip flexion, knee extension and
foot extension. Echocardiography was performed as pre-
viously described [19].
Patient 42 suffers from a 2q37 deletion syndrome in
addition to Pompe disease (unpublished). Since it cannot
be excluded that muscular hypotonia in this patient is
caused by genetic factors other than pathogenic variants
in the GAA gene this patient was excluded from clinical
characterisation [20].
Since parents of patients 2 and 3 are consanguineous,
there are four independent alleles in classic infantile and
73 independent alleles in non-classic patients.
Herzog et al. Orphanet Journal of Rare Diseases 2012, 7:35 Page 3 of 14
http://www.ojrd.com/content/7/1/35All patients were Caucasians, patients 2 and 3 having
a Turkish, the others having a German ancestry.
Biochemical assays
In 32 of the 42 patients GAA activity was measured in
isolated lymphocytes of fresh blood samples with 4-methy-
lumbelliferyl-α-D-glucopyranoside as substrate and acar-
bose as an inhibitor of interfering maltase-glucoamylase
activity according to a standardised protocol [21,22]. The
GAA activity was expressed in nmol hydrolysed 4-MU-
αGlc/hour/mg protein (nmole/mg/hr). In 7 patients GAA
activity was measured according to a former protocol
in isolated lymphocytes with 4-methylumbelliferyl-α-D-
glucopyranoside as substrate without acarbose and in 3
patients enzyme activities were measured in external
laboratories. Those enzyme activities were not included
in further analysis.
Mutation analysis
Direct sequencing of the GAA gene was performed
using standard procedures (Additional file 1). Exons of
the gDNA were amplified using long range PCRs of
eight fragments of the GAA gene. PCR of cDNA was
performed in overlapping fragments as described previ-
ously [23]. To be able to detect or exclude large dele-
tions that escape routine Sanger sequencing long range
PCRs over more fragments were carried out.
Obtained sequences were compared with the reference
sequences NM_000152.3 and NC_000017.9. The A of
the start codon, defining position +1 of cDNA, lies at
positions 3032 and 368 of those sequences, respectively.
The ATG codon represents +1 of the amino acid num-
bering according to NP_00143.2. Variants were described
according to the guidelines of the Human Genome Vari-
ation Society [24]. All nucleotide differences between the
patients and the reference sequence were compared to
the GAA mutation database of the Erasmus MC Univer-
sity Medical Center Rotterdam and to the dbSNP data-
base of the National Center of Biological Information
[9,25]. Variants that were listed as polymorphisms or
assured disease causing mutations in the GAA mutation
database were not further characterised. Novel nonsense
mutations as well as frameshift mutations leading to a
premature stop codon were assumed to be disease caus-
ing if the stop codon was lying upstream of another
known disease causing nonsense mutation. All other
mutations were classified as potentially disease causing
and were further analysed.
The pathogenic nature of novel missense mutations
was verified by restriction digestion or direct sequencing
of 120 alleles of unaffected individuals. Furthermore an
alignment with orthologous sequences was performed.
To identify transcriptional products of splice site
mutations, PCR products were cloned into an expressionvector system. We purified cDNAs using the peqGOLD
MicroSpin Gel Extraction Kit (Peqlab, Erlangen, Germany)
and cloned them into the pGEMW-T vector (Promega,
Mannheim, Germany). After transformation into XL10-
GoldW Ultracompetent Cells (Stratagene, Waldbronn,
Germany) positive clones were selected and plasmid
DNA isolated using the Zyppy™ Plasmid Miniprep Kit
(Zymo research, Freiburg, Germany).
Statistical analysis
Descriptive statistical analysis was performed using
SPSS Statistics version 17.0 (SPSS Software, München,
Germany). Since clinical data were not comprehensive
in all patients, analysis was done with list-wise deletion
of missing values.
Ethics
This study was approved in the context of the Pompe
Registry by the ethics committee of Landesärztekammer
Mainz, Germany.
Results
Disease manifestations in classic infantile patients
Patient 1 was born after an inconspicuous pregnancy
with Cesarean section in the 38th week of gestation
because of a silent cardiotocogram with a birth weight
of 3.6 kg (Table 1, Table 2). Postpartum she had a respir-
atory distress syndrome that required brief ventilation
with facemask. On day three after birth she had myo-
cloni and a periodic breathing with reduced blood oxygen
saturation. In further course she developed a progressive
muscular hypotonia and dystonia with reduction of move-
ments. Left ventricular hypertrophy was diagnosed at the
age of 2.5 month. Diagnosis was made at the age of
3 month. At the start of enzyme replacement therapy at
the age of 5 month, she had generalised muscular hypo-
tonia as well as hypertrophic cardiomyopathy.
Patient 3 was born spontaneously in the 39th week of
gestation with a birth weight of 3.2 kg and developed
initially normal. Aged 2 month she was weak in breath-
ing and sucking. She developed generalised muscular
hypotonia with respiratory insufficiency as well as hyper-
trophic cardiomyopathy.
The diagnostic delay in these two patients was 3 and
1 month, respectively.
The diagnosis in patient 2 was prenatally established
and was based on the finding of hypertrophic cardio-
myopathy. The prenatal development was otherwise
normal and the baby boy was born spontaneously in
the 37th week of gestation with a birth weight of 3.1 kg.
Enzyme replacement therapy was started at the fourth day
of life when the baby boy was still asymptomatic. The
intervention resulted in a regression of cardiomyopathy
Table 1 Clinical, enzymatic and molecular information on 42 German patients with Pompe disease
Patient Age at onset
[years]
First symptoms Walton & Gardner-
Medwin scale
FVC in
sitting/ supine
position [%]
GAA activity
[nmole/mg/hr]
Allele 1 Allele 2 Observation
period
[years]
Gender
classic infantile
1 postnatal respiratory insufficiency - - 1.0$ c.1799G>A c.2481+102_2646+31del 6 f
2 prenatal cardiomegaly - - 0.3$ c.1637-2A>G c.1637-2A>G 2 m
3 3/12 adynamia in breathing
and sucking
- - 1.2$ c.[2740dup;
2742dup]
c.[2740dup; 2742dup] 4/12 f
childhood
4 1 no standing aged 1 year 3 48/50 0.01} c.-32-13T > G c.1051delG 9 m
5 1.5 no free walking aged 1.5 years 8 (walking support
aged 15 years, wheelchair
aged 17 years)
? 0.2$ c.2297A>G c.1561G>A 29 f
6 1.5 no free walking aged 1.5 years 3 32/27 2.0$ c.1370C>T c.1128_1129delinsC 4 m
juvenile
7 1/12 adynamia in breathing
and swallowing
0 75/78 2.1$ c.-32-13T > G c.2481+102_2646+31del 14 m
8 0 muscular hypotonia, adynamia
in swallowing
7 (wheelchair aged
19 years)
32 # c.-32-13T > G c.525delT 21 f
9 1 no standing aged 1 year 2 72/54 0.8$ c.-32-13T > G c.2481+102_2646+31del 30 m
10γ 1 no crawling aged 1 year 0 71/66 0.5$ c.-32-13T > G c.525delT 15 m
11 1 muscle weakness, adynamia
in swallowing
3 80/74 1.2$ c.-32-13T > G c.1548G>A 20 f
12 2 muscle weakness 0 89/86 0.5$ c.-32-13T > G c.118C>T 20 m
13 2 muscle weakness 2 ? 0.02} c.-32-13T > G c.2214G>A 2 f
14 6.5 muscle weakness 0 91/94 0.03} c.-32-13T > G c.1561G>A 5 m
15 3 developmental retardation,
abnormal gait
2 28/20 0.02} c.-32-13T > G c.2738C>G 20 m
16 13 muscle weakness 0 82/75 0.9$ c.-32-13T > G c.-32-13T > G 13 m
17 9 limb girdle weakness 7 (wheelchair aged
33 years)
56/42 2.8$ c.1076-22T > G [c.1426C>A; c.1437+1G>A] 34 f
18β 12 limb girdle weakness 0 98/90 0.3$ c.-32-13T > G c.307T > G 12 f
19 12 limb girdle weakness 0 108/105 1.0$ c.-32-13T > G c.1143delC 25 m
20 13 muscle weakness 3 50/46 0.3$ c.2014C>T c.1703A>T 25 f
21 15 muscle weakness 0 65/60 1.1$ c.-32-13T > G c.1441T>C 17 m
22β 16 muscle weakness 3 69/58 1.2$ c.-32-13T > G c.307T > G 19 f
adult
23 12 weakness of trunk muscles,
scoliosis
4 61/36 0.04} c.-32-13T > G c.1799G>A 48 m
H
erzog
et
al.O
rphanet
Journalof
Rare
D
iseases
2012,7:35
Page
4
of
14
http://w
w
w
.ojrd.com
/content/7/1/35
Table 1 Clinical, enzymatic and molecular information on 42 German patients with Pompe disease (Continued)
24 18 muscle weakness 3 50/25 1.0$ c.-32-13T > G c.1143delC 46 m
25 18 muscle weakness 2 53/30 1.2$ c.-32-13T > G c.701C>A 52 m
26 20 limb girdle weakness 3 71/46 3.9$ c.-32-13T > G c.877G>A 44 f
27α 23 limb girdle weakness 4 (walking support
aged 33 years)
76/68 0.03} c.-32-13T > G c.1291_1299delCTGCACCAG 35 m
28 27 limb girdle weakness 6 (walking support
aged 51 years)
33/26 4.7$ c.-32-13T > G c.1802C>T 53 m
29α 29 limb girdle weakness 0 101/81 0.09} c.-32-13T > G c.1291_1299delCTGCACCAG 42 f
30 30 limb girdle weakness 3 98/90 1.2$ c.-32-13T > G c.525delT 47 f
31 30 limb girdle weakness 3 66/25 1.8$ c.-32-13T > G c.2608C>T 46 f
32 30 backache 1 ? 0.8$ c.-32-13T > G c.1005_1006insGG 70 m
33 35 limb girdle weakness 3 43/19 4.1$ c.-32-13T > G c.1564C>G 45 m
34 35 limb and shoulder girdle
weakness
1 124/105 4.9$ c.-32-13T > G c.307T > G 37 f
35 38 limb girdle weakness 6 (walking support
aged 57 years)
33/18 # c.-32-13T > G c.2214G>A 63 f
36 40 limb girdle weakness 6 (walking support
aged 59 years)
50/37 1.1$ c.-32-13T > G c.2205_2206insT 70 f
37 47 limb girdle myalgia 3 120/119 2.8$ c.-32-13T > G c.2322_2323insGGTGAGTCT-
GCAAACGGGGAGT
59 f
38 48 limb girdle weakness 6 (walking support
aged 62 years)
87/61 0.7$ c.-32-13T > G c.877G>A 62 f
39 56 limb girdle weakness,
backache
2 120/114 1.7$ c.-32-13T > G c.2237G>A 69 f
40 ? ? ? ? 1.5$ c.-32-13T > G c.1687_1688insCACC 65 f
asymptomatic
41γ - asymptomatic 0 95/98 0.4$ c.-32-13T > G c.525delT 20 f
excluded from clinical analysis
42 - - - - # c.-32-13T > G c.2481+102_2646+31del 1 m
α, β siblings
γ first degree cousins.
$ GAA activity measured in isolated lymphocytes with 4-methylumbelliferyl-α-D-glucopyranoside as substrate and acarbose (normal range of 9-42 nmole/mg/hr).
} GAA activity measured according to a former protocol in isolated lymphocytes with 4-methylumbelliferyl-α-D-glucopyranoside as substrate without acarbose (normal range of 0,19-0,45 nmole/mg/hr). Those enzyme
activities were not included in further analysis.
# no own data available.
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Table 2 Disease course in 3 classic infantile patients
Patient 1
Age Disease Course
≤ 0 inconspicuous pregnancy, Cesarean section in the 38th week of gestation because of a silent cardiotocogram, birth weight
of 3.6 kg, respiratory distress syndrome that required brief ventilation with face mask postpartum
3 days myocloni and a periodic breathing with decreased blood oxygen saturation
2.5 month hypotonia, dystonia, reduction of movements, persistent increase of ASAT, ALAT and CK, diagnosis of hypertrophic
cardiomyopathy
5 month generalised muscular hypotonia, movement of extremities possible, hypertrophic cardiomyopathy
start of enzyme replacement therapy
11 month first free sitting with arm support
16 month first rolling, tendency to pull to stand, active crawling, IVSd 7.7 mm [2.6 - 5.6]}
22 month beginning of four point kneeling and crawling, begins supported standing, IVSd 6.9 mm [2.7 – 5.9]
2 4/12 years sitting without arm support with proper head control, supported standing with reduced force of Mm. quadriceps femoris,
IVSd 6.6 mm [2.7 – 5.9]
4 years Unclear speech, stands on hand and feet, and sits unsupported, crawling, good arm control but poor head control, and
hypotonic upper body, IVSd 6.7 mm [3.3 – 6.3]
5 years start of invasive ventilation in supine position because of atelectasis, normalized cardiac function with IVSd 6 mm [3.3 – 6.3]
Patient 2
Age Disease Course
≤ 0 normal prenatal development despite of developing a hypertrophic cardiomyopathy, spontaneous delivery in the 37th week
of gestation, birth weight of 3.1 kg
4 days start of enzyme replacement therapy, IVSd 6.7 mm [2.3 – 4.9]
2 month head control for 2-3 sec. when pulled up from supine position, IVSd 6.6 mm [2,4 – 5,2]
5 month normal development, normal force, lifts head actively in prone position, rolling from prone to supine position and back,
IVSd 5 mm [2.5 – 5.3]
8 month normal development, supported standing, crawling, free sitting, normal force, IVSd 6 mm [2.6 – 5.6]
11 month independent walking and standing
15 month normal development, normal force, walking but a bit waddling, discrete Facies hypotonica, proper standing up without
Gower´s sign, IVSd 5 mm [2.6 – 5.8]
Patient 3
≤ 0 inconspicuous pregnancy, spontaneous delivery in the 39th week of gestation, birth weight of 3.2 kg
2 month weak in breathing and sucking
3 month generalised muscular hypotonia with respiratory insufficiency, cyanosis, hypertrophic cardiomyopathy, IVSd 10 mm [1.4 – 3.8]
start of enzyme replacement therapy
data on the further course are not yet available
} Normal values of IVSd according to Kampmann et al. 2000 [19].
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the 2 years follow-up period.
Disease manifestations in non-classic patients
The observation period of the included 37 symptomatic
non-classic patients ranges from 1.5 to 70 years with a
median of 30 (Quartiles: 18, 47) years. Age at onset is
known in 36 of them and spans from birth to the age of
56 years with a median of 14 (Quartiles: 2, 30) years.
The first symptoms of these patients are categorised in
Figure 1.
In four patients it came to a temporary regression of
symptoms in childhood or adolescence before their
muscle weakness became progressive. Patient 8 had had
an early disease onset with postnatal muscular hypotoniaand adynamia in swallowing. Her muscular weakness
had improved until she developed a proximal muscle
weakness at the age of 8 years, which was rapidly pro-
gressive and led to wheelchair dependence at the age of
19 years. Patient 9 also had an early onset disease with
delayed motor milestones. He reached standing at one
year of age and was able to walk aged 3 years. He did
well until the age of 17 years, when he was resilient and
active, before muscle weakness progressed. Patient 12
suffered from generalised muscular hypotonia at the age
of 2 years. His fitness considerably improved during
childhood and has remained stable over the observation
period until the age of 20 years. Patient 23 manifested
weakness of trunk muscles and scoliosis at the age of
12 years, but his fitness improved till the age of 25 years
Figure 1 Frequency of first symptoms in non-classic patients.
About one third of the patients had mild symptoms in childhood
preferentially consisting of delayed motor milestones and
feeding problems.
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ness began in his middle twenties and proceeded until
the end of the observation period.
Patients were diagnosed between 5 month and 66 years
of age with the median age of 22 (Quartiles: 4, 44) years
(n = 36). The median diagnostic delay in symptomatic
patients was 8 (Quartiles: 2, 15) years, ranging from 0 to
34 years (n = 36).
At the end of the observation period 29 of 37 included
symptomatic patients (78%) were able to walk without
any assistance while 5 (14%) needed a supportive device
and 3 (8%) a wheelchair. Walking assistance was first
used at the median age of 54 (Quartiles: 28, 60) years
ranging from 15 to 62 years (n = 6). Disease duration
until usage of walking assistance had a median of 19
(Quartiles: 12, 21) years ranging from 10 to 24 years
(n = 5). The 3 patients using a wheelchair became
dependent on it at the age of 17, 19 and 33 years after
disease duration of 16, 19 and 24 years. The mobility of
each patient graded according to the Walton &
Gardner-Medwin scale is shown in Table 1. The median
muscle strength of different muscle groups according to
MRC is shown in Figure 2.
Patient 5 needed continuous invasive ventilation since
the age of 27 years after disease duration of 26 years.
Eight patients (22%) used non-invasive ventilation while
lying. Non-invasive ventilation was started at the median
age of 46 (Quartiles: 21, 48) years ranging from 19 to
63 years (n = 9) after disease duration of 21 (Quartiles:
17, 27) years ranging from 11 to 29 years (n = 9). FVC in
sitting position had a median value of 71% (Quartiles:
50, 92) of normal with a range of 28 to 124% (n = 34). It
decreased to 60% (Quartiles: 33, 88) in the supine pos-
ition with a range of 18 to 119% (n = 33).
To further explore disease progression we analysed the
correlations between clinical parameters and age as well
as disease duration that are given in Table 3.Acid alpha-glucosidase activity and clinical course
Enzyme activities in lymphocytes of the three classic
infantile patients were 1.0, 0.3 and 1.2 nmole/mg/hr
(Normal range 9–42 nmole/mg/hr). Residual activities of
30 non-classic patients ranged from 0.2 to 4.9 nmole/
mg/hr with a median of 1.1 (Quartiles: 0.8, 2.0) nmole/
mg/hr. Figure 3 shows the enzyme activities in the dif-
ferent courses of non-classic disease. The Wilcoxon-
Mann–Whitney-test revealed significant higher activities
in patients with an adult course than in patients with a
juvenile course (p = 0.016).
In the group of non-classic patients there was a trend
towards later onset of symptoms with higher enzyme
activities (rs = 0.354, p = 0.070). No correlation was found
between the enzyme activity and the current disease
severity (i.e. the sum of muscle strength according to
the MRC for the different muscle groups and the forced
vital capacity).
Serum enzymes
Serum values of creatine kinase (CK), lactate dehydro-
genase (LDH), alanine aminotransferase (ALAT) and
aspartate aminotransferase (ASAT) were elevated in nearly
all patients. Their distribution is shown in Table 4.
Mutation spectrum
Mutations were identified in each of the 77 alleles
(Table 1). Figure 4 shows their random distribution over
the GAA gene, Table 5 their frequency and predicted ef-
fect [9,25,26]. Of the 33 different variants that we identi-
fied, 14 (42%) had not been reported previously.
Novel mutations
In total, we identified 14 novel mutations. Six of them
lead to a premature stop in protein synthesis (c.1005_
1006insGG, c.1143delC, c.1687_1688insCACC, c.2205_
2206insT, c.2214 G>A and c.2322_2323insGGTGAGT-
CTGCAAACGGGGAGT). One splice site mutation
c.1437 + 1 G>A occurring ‘in cis’ with c.1426 C>A
(p.Leu476Met) was found compound heterozygous with
the intronic mutation c.1076-22 T>G, also causing
aberrant splicing. Cloning of the transcriptional products
into an expression vector system demonstrated that
there were no normally spliced products derived from
the c. [1426 C>A; 1437+ 1 G>A] allele. The alterna-
tively spliced products derived from the c.1076-22 T>G
allele had the wild type cytosine at position c.1426. Thus
the variants at position c.1426 C>A (p.Leu476Met) and
c.1437 + 1 G>A are located on the same allele. In the
solely identified splice product of the c. [1426 C>A;
1437+ 1 G>A] allele exon 9 was skipped (r.1327_
1437del), which results in a protein bearing the in frame
deletion p.Asp443_Lys479del.
Figure 2 Muscle strength of different muscle groups in non-classic patients according to MRC. The median muscle strength shows a
predominant involvement of proximal muscles. The lower limbs are most affected.
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appeared to fully prevent correct splicing. Instead, 5 al-
ternative splice products could be cloned all of which
lack the 5´-end of exon 12. Amplification of cDNA with
CTG GAG GGT CCC CCC AAC CAC C as reverse pri-
mer located in this region did not reveal any products.
Furthermore, five novel missense mutations and one
deletion of 9 nucleotides were identified (c.701 C>A
(pThr234Lys) c.1703A>T (p.His568Leu), c.1802 C>T
(p.Ser601Leu), c.2297A>G (p.Tyr765Cys), c.2738 C>
G (p.Pro912Arg) and c.1291_1299delCTGCACCAG
(p.Leu431_Gln433del)). These mutations were not encoun-
tered among 120 alleles of unaffected persons. The cor-
responding amino acids are highly conserved among all
compared eutheria (Additional file 2).Genetic variability
We analysed 34 SNPs located within the sequenced
areas and compared their frequencies to those of refer-
ence populations (Additional file 3) [9,25,27].Table 3 Correlation of clinical parameters with age and disea
Correlation with a
Spearman-Rho
Total MRC-score -0.491
Walton & Gardner-Medwin Scale 0.451
FVC supine -0.214
FVC sitting 0.001In patients bearing the c.-32-13 T>G mutation the
variants c.324 C>T (p.Cys108Cys), c.596 G>A (p.
Arg199His), c.668A>G (p.His223Arg), c.1203A>G (p.
Gln401Gln), c.1327-18 G>A, c.2040 + 20 G>A and
c.2338A>G (p.Ile780Val) appear considerably more fre-
quent than in reference collectives (Hapmap-CEU, AoD
Caucasian). In patients not bearing c.-32-13 T>G the
frequencies of these polymorphisms are similar to those
of the reference collectives.
In the 5´-untranslated region of the GAA gene we identi-
fied the novel polymorphism c.-367-157 C>G on 9/52
alleles of the patients bearing the c.-32-13 T>G mutation.Genotype-phenotype correlations
All three patients with classic infantile Pompe disease
had two severe mutations. In the patients with non-
classic disease we analysed the disease manifestation
according to the prevalence of the common c.-32-13 T>
G mutation. Patient 16 is homozygous for c.-32-13 T>G
as was confirmed by demonstrating heterozygosity ofse duration in patients with non-classic disease
ge Correlation with disease duration
Significance Spearman-Rho Significance
0.006 -0.543 0.002
0.005 0.481 0.003
0.231 -0.507 0.003
0.994 -0.399 0.021
Figure 3 Correlation between disease course and residual acid
alpha-glucosidase activity in lymphocytes.
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13 years by a reduced resilience with a slight muscle
weakness. In c.-32-13 T>G genetic compounds the
Log-Rank test showed a later onset compared to patients
with other mutations (p = 0,025) (Figure 5). The age at
onset of c.-32-13 T>G genetic compounds was 18
(Quartiles: 2, 30) years ranging from 0 to 56 years
(n = 31). Four patients bearing two other mutations had
first symptoms at the age of 1.5, 1.5, 9 and 13 years re-
spectively. In summary the c.-32-13 T>G mutation is
associated with a later disease manifestation.
Discussion
Disease manifestations in classic infantile patients
Until the start of ERT, patient 1 (at 5 month of age) and
patient 3 (at 3 month of age) had a characteristic course
with hypertrophic cardiomyopathy and respiratory pro-
blems resulting from muscular hypotonia developing in
the first month of life [3,28]. The hypertrophic cardio-
myopathy of patient 2 was discovered prenatally and
ERT was started on day 4 after birth. This early inter-
vention resulted in normalisation of the left ventricular
wall thickness and a near normal development of theTable 4 Serum enzymes of 2 patients with classic
infantile and 29 patients with non-classic disease
CK [U/l] LDH [U/l] ALAT [U/l] ASAT [U/l]
Reference values 30-200 < 245 < 50 5-35
Median 607 363 94 82
Minimum 148 242 40 25
25th percentile 388 302 62 64
75th percentile 899 476 188 154
Maximum 2256 1416 548 532
There were not found significant differences in serum enzymes depending on
the different courses of disease.child up to the age of 2 years, in contrasts to the natural
course of disease whereby higher motor milestones are
not reached. Notably, similar effects have been reached
by newborn screening and immediate initiation of ERT
in 5 patients with classic infantile Pompe disease from
Taiwan [29]. ERT in patient 1, who was already symp-
tomatic at the start of therapy, resulted in a reduction of
the left ventricular wall thickness to normal values and
delayed, but not prevented, the occurrence of typical
symptoms. This confirms previous findings that the out-
come of enzyme replacement therapy depends on the
clinical status of the patient at start of treatment and
underlines the relevance of an early diagnosis followed
by an immediate intervention [30].
Disease manifestations in non-classic patients
There is a broad heterogeneity in the clinical course of
non-classic Pompe disease with onset between birth and
late adulthood. In our study the median age of onset was
considerably younger than in previous studies [4,13].
This is explained in part by the fact that we have inter-
preted any symptom that probably relates to Pompe dis-
ease as disease onset while in other studies the
beginning of progressive muscle wasting was mostly
taken as first symptom. Accordingly the spectrum of
first symptoms differs. Though muscle weakness is the
most frequent initial symptom, other complaints like
delayed achievement of motor milestones or feeding
problems in childhood appear rather common [4,13].
With regard to the diagnostic delay of 8 years these find-
ings emphasise the necessity of being aware that non-
classic forms of Pompe disease can manifest in the first
years of life. Additional sensitive hints can be given by
serum values of CK, LDH, ALAT and ASAT that were
clearly elevated in nearly all patients. Elevations of LDH,
ASAT and ALAT in daily diagnostic routine can point to
a muscle disease and should be further investigated by
determining the CK even in asymptomatic patients.
Since the efficacy of enzyme replacement therapy
depends on the clinical state at start of therapy, it is im-
portant to diagnose patients before the disease has pro-
gressed to muscle wasting [31]. Remarkably, none of our
patients initially had respiratory complaints in contrast
to other studies wherein approximately one third of the
patients had respiratory symptoms before locomotive
problems manifested [5,13]. This might be explained by
a difference in data acquisition, whereby we extracted
the first symptoms from the patients’ health reports.
The absence of subjectively sensed disorders does not
exclude the prevalence of a relevant respiratory
insufficiency.
Progressive muscle wasting was the salient clinical
feature. The characteristic pattern of involvement of dif-
ferent muscle groups described previously could be
Figure 4 Mutation spectrum in 42 German patients. Previously described mutations are shown above and new mutations below the
diagrammed GAA gene (red: URT, blue: introns, green: exons).
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ment from the distal to the proximal muscles while the
lower limbs are more affected than the upper limbs.
Reduced strength of skeletal muscles leads to impaired
walking and breathing, but the range of functional loss is
very broad. Reduction of force and muscle function were
correlated with age and disease duration and forced vital
capacities were correlated with disease duration showing
the progressive course of Pompe disease.
Mutation analysis
Since molecular defects causing Pompe disease are
numerous with most mutations appearing only sporadic-
ally, sequencing is the most appropriate method for their
analysis [16,33]. To prevent the missing of large dele-
tions we analysed both genomic DNA as well as cDNA
in large fragments. By this we reached a sensitivity of
100%. Furthermore, we investigated all newly discovered
sequence variants for their pathogenic nature in order to
exclude false positive identification.
Mutation spectrum
Our study underlines the enormous heterogeneity at
the GAA locus that has come to light in a number of
studies that were performed over the past ten years. As
much as 73% (24 out of 33) of all mutations that we
identified in our present study were only encountered
once [9–14,33–35].
The very frequent observation of the c.-32-13 T>G
mutation among the German patients studied (34 of the
38 children and adults) corresponds with the previously
reported high frequency of this mutation in patients
from Central and Southern Europe [10–14]. We also
encountered the deletions of exon 18 (c.2481+102_
2646+31del) and c.525delT in several patients, but these
two mutations seem not as common in the German as in
the Dutch population [10–14,34,35]. Furthermore, ourstudies confirmed that the missense mutations c.307 T>G
and c.877 G>A are probably more frequent in Germany
than in other European countries [14,16,35].
Novel mutations
All the protein truncating mutations that were identified
in this study are assumed to be deleterious since their
stop codons are located upstream of those that are
known to result in a complete loss of enzyme activity [9].
The complex mutation c.[1426 C>A; 1437 + 1 G>A]
leads to exon 9 skipping. The concurrence of this muta-
tion together with the mild splice site mutation c.1076-
22 T>G in a patient with onset of symptoms at the age
of 9 years and wheelchair dependency at the age of
33 years indicates that c.[1426 C>A; 1437 + 1 G>A]
probably leads to complete loss of function [36].
Regarding the mutation c.1637-2A>G the absence of
any normally spliced product conforms to the classic in-
fantile course of Pompe disease in patient 2 who is
homozygous for this mutation.
The disease causing effect of some of the novel mis-
sense mutations and of the 9 base pairs deletion was not
directly proven, since no functional studies were carried
out. Yet, their absence on 120 alleles of unaffected per-
sons as well as patients together with the conservation
of the affected amino acids among the twenty-two
eutheria (Additional file 2) makes it very likely that
they are disease causing. The substitution c.1802 C>T
(p.Ser601Leu) is the third mutation discovered in this
codon. Previously, c.1802 C>G (p.Ser601Trp) and
c.1802 C>A (pSer601X) were reported as pathogenic
sequence variations [37,38]. We found the c.2297A>G
mutation in a patient with a childhood course of the dis-
ease compound heterozygous with the base exchange
c.1561 G>A that leads to a total loss of enzyme activity
[39]. These findings indicate that c.2297A>G allows for
a low residual activity.
Table 5 Frequency and predicted effect of identified mutations
Mutation Effect on cDNA or protein Predicted severity [9,25,26] Frequency
c.-32-13T>G impaired splicing of exon 2 mild 34/73 alleles in non-classic
patients
c.118C>T p.Arg40X severe 1/42 alleles at risk
c.307T>G p.Cys103Gly severe 2/42 alleles at risk
c.525delT p.Glu176fsX45 severe 3/42 alleles at risk
c.701C>A p.Thr234Lys potentially less severeα 1/42 alleles at risk
c.877G>A p.Gly293Arg severe 2/42 alleles at risk
c.1005_1006insGG p.Ile336GlyfsX56 severe 1/42 alleles at risk
c.1051delG p.Val351CysfsX41 severe 1/42 alleles at risk
c.1076-22T>G p.[Asp319_Val358delinsGlySerArgArgTrpProAla;
Gly334_Val358delinsGlySerArgArgTrpProAla]
mild 1/73 alleles in non-classic
patients
c.1128_1129delinsC p.Trp376CysfsX16 severe 1/42 alleles at risk
c.1143delC p.Thr381fsX10 severe 2/42 alleles at risk
c.1291_1299delCTGCACCAG p.Leu431_Gln433del unknown 1/77 alleles
c.1370C>T p.Pro457Leu mild 1/73 alleles in non-classic
patients
c.[1426C>A; 1437+1G>A] r.1327_1437del p.Asp443_Lys479del unknown 1/77 alleles
c.1441T>C p.Trp481Arg severe 1/42 alleles at risk
c.1548G>A p.Trp516X severe 1/42 alleles at risk
c.1561G>A p.Glu521Lys severe 2/42 alleles at risk
c.1564C>G p.Pro522Ala severe 1/42 alleles at risk
c.1637-2A>G r.[1637_1659del; 1637_1682del; 1637_1738del;
1637_1754del; [1637_1659del, 1755-110_1755-1ins]]
p.[V547GfsX80; G546AfsX16; G546_E579del;
V547RfsX2; V547_R585delinsGGHHLCLQPPVSLH-
TLQPAQPLRPDRSHRLPOPLPHPRKLLAPSSALLVTG-
FPSPPAPHSPHGVPHHPR]
severe 1/42 alleles at risk
c.1687_1688insCACC p.Gln563ProfsX73 severe 1/42 alleles at risk
c.1703A>T p.His568Leu unknown 1/77 alleles
c.1799G>A p.Arg600His severe 2/42 alleles at risk
c.1802C>T p.Ser601Leu potentially less severeα 1/77 alleles
c.2014C>T p.Arg672Trp intermediate 1/77 alleles
c.2205_2206insT p.Ser736Xfs severe 1/42 alleles at risk
c.2214G>A p.Trp738X severe 2//42 alleles at risk
c.2237G>A p.Trp746X severe 1/42 alleles at risk
c.2297A>G p.Tyr765Cys unknown 1/77 alleles
c.2322_2323insGGTGAGTCT-
GCAAACGGGGAGT
p.Leu775GlyfsX70 severe 1//42 alleles at risk
c.2481+102_2646+31del p.Gly828_Asn882del severe 4//42 alleles at risk
c.2608C>T p.Arg870X severe 1//42 alleles at risk
c.2738C>G p.Pro912Arg unknown 1/77 alleles
c.[2740dup; 2742dup] p.Gln914fsX30 severe 1//42 alleles at risk
α unpublished data, that will be included in the upcoming update of the Pompe disease mutation database
novel mutations in bold italics.
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assessed by functional studies. This would provide the
highest insight in the functional effects of the sequence
variations as well as the best basis for investigating
genotype-phenotype correlation.Genetic variability
The comparison of the frequencies of 34 polymorphisms
with reference populations revealed an association of the
mutation c.-32-13 T>G with the haplotype [c.324 T,
c.596A, c.668 G, c.1203 G, c.1327-18A, c.2040 + 20A,
Figure 5 Kaplan-Meier function of age at disease onset
depending on the prevalence of the common mutation c.-32-
13 T>G.
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c.1726 G>A, c.2065 G>A, c.2446 G>A and c.2780 C
>T rarely appear in this cohort the common mutation
seems to be associated with the haplotype DHRGEVVT
(c.271 G, c.596A, c.668 G, c.1726 G, c.2065 G, c.2338 G,
c.2446 G, c.2780 C) in the German population. This
association is in line with previous findings in the
European population and corroborates the hypothesis of
a founder effect [18].
Genotype-phenotype correlations
The primary effect of residual enzyme activity on the
clinical course of Pompe disease can be confirmed
[2,3,10,16,17,40]. All our classic infantile patients had
virtually no enzyme activity due to two severe mutations.
Residual activities in non-classic patients correlated with
a later age of onset and slower disease progression. All
subgroups harboured patients with very low activities.
Yet, the highest values were found among the patients
with an adult course of the disease. Thus, high residual
activities protect against a severe course of disease.
Current disease severity did not correlate with enzyme
activity although proof of this correlation is difficult to
show in such small cohorts with a broad range of
current age.
As in previous studies, the most common c.-32-13 T>
G mutation is associated with a milder course although
there is a broad variability in the decline of locomotive
and respiratory function [4,11,13,18]. This is underlined
by the discovery of a c.-32-13 T>G homozygous pa-
tient. Since homozygous patients were only sporadically
reported it can be assumed that the homozygous state of
c.-32-13 T>G usually is none-penetrating [13,41,42].
Phenotypic variability points to disease modifying factors
that obtain relevance when the underlying pathogenicmutations allow for appreciable residual activity [18] The
broad range of enzyme activities in c.-32-13 T>G com-
pound heterozygous patients that cannot be described to
the nature of the mutations on the second allele speaks
for factors modulating the expression of the GAA gene,
alternative splicing or the maturation of the translational
products [43,44]. Variation can also be envisaged to
develop on the basis of qualitative and quantitative dif-
ferences in the autophagy pathway that influence the
lysosomal glycogen deposition [45].
The fact that three of four patients who had a tem-
poral regression of symptoms where quite active might
indicate that muscle training can ameliorate the course
of disease [46]. Muscle regeneration decreases with age,
but is enhanced by training and proper nutrition, espe-
cially in young people [47,48]. It is certainly worthwhile
to further elucidate the regulation of muscle plasticity
and regeneration in future studies.
Conclusions
This study is one of the largest single-centre studies
regarding phenotypes as well as genotypes in Pompe dis-
ease. The disease course is dominated by progressive
locomotive and respiratory impairment in all patients
and and hypertrophic cardiomyopathy in patients with
classic infantile disease. The clinical spectrum strongly
correlates with residual acid alpha-glucosidase activity.
Residual activity of this enzyme is primarily determined
by the severity of the pathogenic mutations on both
GAA alleles and likely controlled by yet unknown modi-
fying factors.
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